NCT06417281View on ClinicalTrials.gov

Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid（5-ALA）

PHASE3RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 19, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
5-aminolevulinic AcidMalignant Glioma of Brain
Interventions
DRUG

5 Aminolevulinic Acid

3±1 hours before anesthesia, participants will take 5-ALA orally at a dosage of 20 mg/kg, followed by fluorescence-guided resection of malignant glioma.

Trial Locations (1)

Unknown

RECRUITING

Huashan Hospital, Fudan University, Shanghai

All Listed Sponsors
lead

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

INDUSTRY